MARC Record from harvard_bibliographic_metadata

LEADER: 05717cam a2200553 a 4500
001 000522414-4
005 20020606090541.3
008 860108s1986 nyua b 11110 eng d
010 $a 85032557 //r86
020 $a0306422301 (pt. A)
020 $a030642231X (pt. B)
035 0 $aocm13002578
035 0 $aocm13092417
040 $aDNLM/DLC$cDLC$dOCL$dm/c$dHMS
050 0 $aRC632.P87$bI58 1985
060 00 $aW1$bAD559 v.195 1986
060 10 $aWD 205.5.P8$bI605 1985p
082 0 $a616.3/9$219
111 2 $aInternational Symposium on Human Purine and Pyrimidine Metabolism$n(5th :$d1985 :$cSan Diego, Calif.)
245 10 $aPurine and pyrimidine metabolism in man V /$cedited by W.L. Nyhan, L.F. Thompson, and R.W.E. Watts.
246 3 $aPurine and pyrimidine metabolism in man five
246 3 $aPurine and pyrimidine metabolism in man 5
260 0 $aNew York :$bPlenum Press,$cc1986.
300 $a2 v. :$bill. ;$c26 cm.
440 0 $aAdvances in experimental medicine and biology ;$vv. 195
500 $a"Proceedings of the Fifth International Symposium on Human Purine and Pyrimidine Metabolism, held July 28-August 1, 1985, in San Diego, California"--T.p. verso, v. 1.
500 $a"Festschrift for J.E. Seegmiller."
504 $aIncludes bibliographies and indexes.
505 0 $apt. A. Clinical aspects including molecular genetics -- pt. B. Basic science aspects.
520 $aThe Fifth International Symposium on Human Purine and Pyrimidine Metabolism was held in San Diego, California (U.S.A.) in July and August of 1985. Previous meetings in this series were held in Tel Aviv (Israel), Baden (Austria), Madrid (Spain) and Maastricht (The Netherlands). The proceedings of each of these meetings were published by Plenum. The next meeting will be in Japan. This Symposium differed from those that went before in that it permitted us to honor Dr. J. E. Seegmiller, Professor of Medicine at the University of California San Diego, for his many contributions to our understanding of purine metabolism in man. This publication is dedicated as a Festschrift to Jay. Dr. Richard W. E. Watts delivered the keynote address outlining in scholarly fashion the history of Dr. Seegmiller's accomplishments in research on purine metabolism and the great number of currently active scientists in this field who have worked with him.
520 $aThis address is published as the first contribution to Volume I. Dr. Dewitt Stetten, Jr., was scheduled to be the speaker at our banquet. Unfortunately, he could not be with us. Dr. Seegmiller has written an appreciation of Dr. Stetten and his contributions to our field, and this has been published following Dr. Watts' paper. The growth of knowledge in purine and pyrimidine metabolism continues to be exponential. The variety of subjects included in these volumes is impressive. New or previously unrecognized disorders of purine metabolism continue to be uncovered. An entire section on disorders of purine and pyrimidine metabolism other than deficiency of HPRT is led off by two papers on adenylosuccinase deficiency. Among the disorders of pyrimidine metabolism there are papers on orotic aciduria and dihydrothymine dehydrogenase deficiency. Clinical and biochemical studies of gout and urolithiasis continue to be actively pursued.
520 $aAt the same time the study of purine metabolism has become an integral feature of immunology. The importance of purines in clinical oncology was first demonstrated with the synthesis by George Hitchings of 6-mercaptopurine. Its continuing impact on hematology and oncology is seen throughout these volumes, particularly in the effects of inhibition of adenosine deaminase on T cells and on T cell leukemia. This publication has implications for internal medicine, pediatrics, urology, biochemistry, immunology, genetics, hematology, and oncology. Modern molecular biology and techniques involving recombinant DNA were evident in papers on HPRT and on adenosine deaminase, as well as in studies on APRT and UMP synthase. The genes for HPRT, adenosine deaminase and puine nucleoside phosphorylase have been cloned. The background for ultimate approaches to gene therapy in man was provided in papers from Dr.
520 $aSeegmiller's laboratory on the insertion of HPRT cDNA into human bone marrow cells and on metabolic cooperation. Purine receptors have been discovered in the central nervous system, in lymphocytes and in a variety of other tissues. There are also adenosine receptors in Leishmania and a number of purine riboside analogs are under study as potential therapeutic agents in leishmaniasis.
600 10 $aSeegmiller, J. E.$vCongresses.
650 2 $aPurine-Pyrimidine Metabolism, Inborn Errors$xcongresses.
650 2 $aPurines$xmetabolism$xcongresses.
650 2 $aPyrimidines$xmetabolism$xcongresses.
600 12 $aSeegmiller, J. E.
650 0 $aPurines$xMetabolism$xDisorders$vCongresses.
650 0 $aPyrimidines$xMetabolism$xDisorders$vCongresses.
655 7 $aConference proceedings.$2fast
700 1 $aNyhan, William L.,$d1926-
700 1 $aThompson, L. F.$q(Linda Frances),$d1947-
700 1 $aSeegmiller, J. E.
700 1 $aWatts, R. W. E.
776 08 $iOnline version:$aInternational Symposium on Human Purine and Pyrimidine Metabolism (5th : 1985 : San Diego, Calif.)$tPurine and pyrimidine metabolism in man V.$dNew York : Plenum Press, c1986$w(OCoLC)685221482
776 08 $iOnline version:$aInternational Symposium on Human Purine and Pyrimidine Metabolism (5th : 1985 : San Diego, Calif.).$tPurine and pyrimidine metabolism in man V.$dNew York : Plenum Press, ©1986$w(OCoLC)685221482
988 $a20020608
906 $0OCLC